Literature DB >> 4404080

Plasma levels in man of nitroglycerin after buccal administration.

M G Bogaert, M T Rosseel.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4404080     DOI: 10.1111/j.2042-7158.1972.tb09100.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


× No keyword cloud information.
  8 in total

1.  Comparison of effects of tolmesoxide (RX71107), diazoxide, hydrallazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man.

Authors:  J G Collier; R E Lorge; B F Robinson
Journal:  Br J Clin Pharmacol       Date:  1978-01       Impact factor: 4.335

2.  Circulatory effects of sublingual and oral sustained-release nitroglycerin in healthy young men.

Authors:  G Nyberg; H Westling
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

3.  Quantitation of nitroglycerin in human blood after administration by sustained release.

Authors:  Y Givant; F G Sulman
Journal:  Experientia       Date:  1978-05-15

Review 4.  Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations.

Authors:  M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its metabolites.

Authors:  Satoru Hashimoto; Atsuko Kobayashi
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of nitrates.

Authors:  M G Bogaert
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

Review 7.  Clinical pharmacokinetics of organic nitrates.

Authors:  M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

8.  Nitroglycerin stimulates synthesis of prostacyclin by cultured human endothelial cells.

Authors:  R I Levin; E A Jaffe; B B Weksler; K Tack-Goldman
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.